Dr. Budde is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Division of Lymphoma
1500 East Duarte Road
Duarte, CA 91010Phone+1 626-256-4673Fax+1 626-389-3058- Is this information wrong?
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 2006 - 2009
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
- Duke UniversityPh.D., 1995 - 2001
- Tongji Medical UniversityClass of 1995
Certifications & Licensure
- CA State Medical License 2012 - 2024
- WA State Medical License 2006 - 2013
Awards, Honors, & Recognition
- Clinical investigator Damon runyon cancer research foundation
Clinical Trials
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Start of enrollment: 2007 Dec 01
- Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
- Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Start of enrollment: 2015 Dec 15
- Join now to see all
Publications & Presentations
PubMed
- CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.Sumanta K Pal, Ben Tran, John B A G Haanen, Michael E Hurwitz, Adrian Sacher, Nizar M Tannir, Lihua E Budde, Simon J Harrison, Sebastian Klobuch, Sagar S Patel, Luis M...> ;Cancer Discovery. 2024 Apr 5
- Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.Lihua E Budde, Sarit Assouline, Laurie H Sehn, Stephen J Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, ...> ;Journal of Clinical Oncology. 2024 Mar 28
- Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.James K Godfrey, Lei Gao, Geoffrey Shouse, Joo Y Song, Stacy Pak, Brian Lee, Bihong T Chen, Avyakta Kallam, John H Baird, Guido Marcucci, Lucy Y Ghoda, Stephanie Vaule...> ;Blood. 2024 Mar 14
- Join now to see all
Abstracts/Posters
- Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative AnalysisLihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid LeukemiaLihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
- City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
- Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell LymphomaDecember 23rd, 2023
Other Languages
- Chinese (Mandarin)
Hospital Affiliations
- City of Hope Comprehensive Cancer CenterDuarte, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: